Why Regado Biosciences (RGDO) Stock Is Plummeting Today

NEW YORK (TheStreet) -- Regado Biosciences (RGDO) shares are cratering, down over 50% to $2.94, on Thursday after the Data Safety Monitoring Board recommended that patients in the company's REGULATE-PCI drug trial stop being dosed due to allergic reactions following an unplanned review of the trials.

The company announced that patient enrollment for the blood clot treatment trials will be halted until the review, which is expected to take a couple of months, is completed.

Must ReadWarren Buffett's 25 Favorite Stocks

RGDO Chart

RGDO data by YCharts

If you liked this article you might like

5 Stocks Ready to Break Out and Soar Higher

3 Biotech Stocks Under $10 in Breakout Territory

3 Biotech Stocks Under $10 to Trade for Breakouts

Why Regado Biosciences (RGDO) Stock Hit a One-Year Low Today

3 Stocks Under $10 to Trade for Breakouts